The Effects of Cholecalciferol Supplementation on Serum Angiogenic Biomarkers in Breast Cancer Patients Treated with Tamoxifen: a Controlled Randomized Clinical Trial

Abstract Objective The aim of this study was to investigate the effects of cholecalciferol supplementation on serum levels of angiogenic parameters in breast cancer (BC) patients treated with tamoxifen (TAM). Research Methods & Procedures In this pilot-based randomized, triple-blind, placebo-controlled clinical trial, 52 BC patients randomly assigned into either intervention group received weekly 50000 IU cholecalciferol and the placebo group for 8 weeks. At the baseline and the end of the study, serum levels of angiogenic growth factors such as vascular endothelial growth factor-A (VEGF-A), angiopoietin-2 (Ang-2), hypoxia-inducible factor-1 (Hif-1) and high sensitivity C-reactive protein (HSCRP) were measured by ELISA. Every four weeks, a completed 3 days 24-hour dietary record and daily sunlight exposure checklist were collected and anthropometric variables were measured (IRCT Registry No.: IRCT2015082111335N6). Results The ultimate number of participants at each arm was 22 for analyses. For pre-menopausal women, cholecalciferol supplementation resulted in a significant decrease in serum levels of Ang-2 and VEGF-A after 8 weeks of treatment (p Conclusion Cholecalciferol supplementation had received sufficient efficacy among BC patients consuming TAM and could be effective in the reduction of angiogenic biomarkers particularly dependent on the infiltration status of the tumor to vessels. Further studies with larger subgroups needed to be investigated.